MX1 – Morgans rates the stock as Add

The third quarter cashflow report shows to Morgans the business is well funded to achieve a number of key growth objectives over the next three years.

Nano sales are expected to accelerate in upcoming quarters, with additional distributor agreements a likely catalyst, explains the broker. Another catalyst is considered to be regulatory clearance for the Rover in Europe.

The Buy (Speculative) and $0.61 price target are unchanged. The downside risk is a delay in securing further Nano and Rover orders, cautions the analyst.

Sector: Health Care Equipment & Services.


Target price is $0.61.Current Price is $0.33. Difference: $0.28 – (brackets indicate current price is over target). If MX1 meets the Morgans target it will return approximately 46% (excluding dividends, fees and charges – negative figures indicate an expected loss).



Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →